Havrix-1440 vaccine
Use of Havriks-1440 vaccine
Havrix is intended for intramuscular administration. For adults, the vaccine is injected into the area of the deltoid muscle.
Primary vaccination
Adults 19 years of age and older. For the primary immunization of adults, a single dose of Havriks™ 1440 vaccine (adult dose) (1.0 ml of suspension) is used.
Booster vaccination
After the primary vaccination with Havrix™ 1440 (adult dose) to ensure long-term immune protection, it is recommended to administer a booster dose of the vaccine. This booster dose should be given anytime between 6 months and 5 years after the first dose, but preferably between 6 and 12 months after the first dose of vaccine.
-
What are the indications for Havriks-1440 vaccine?
Havrix™ vaccine is intended for active immunization of persons who are at risk of infection with the hepatitis A virus. The vaccine does not prevent infection caused by other pathogens, for example, hepatitis B, hepatitis C, hepatitis E viruses or other pathogens that cause other liver diseases .
In areas with low and moderate hepatitis A endemicity, it is recommended to immunize with Havriks™ vaccine first of all persons who constitute or may constitute groups of increased risk of infection.
-
What are the contraindications to the Havriks-1440 vaccine?
Havrix™ should not be administered to individuals with known hypersensitivity to any component of the vaccine, or in the presence of hypersensitivity reactions after previous administration of Havrix™ vaccine.
-
What are the side effects of Havrix-1440 vaccine?
After vaccination can be observed:
- loss of appetite;
- irritability;
- drowsiness;
- nausea;
- diarrhea;
- temperature increase;
- redness;
- rash;
- pain and swelling at the injection site.
In the presence of mechanical inclusions or a strange color of the solution, the use of the vaccine is unacceptable.
The price of Havriks-1440 vaccine | 1700 UAH |
Against what: Availability of vaccine in Kharkiv: